AVAPRITINIB RESISTANCE OF KIT MUTANTS
The disclosure includes methods of treating a patient suffering from a malignant disease driven by activating mutations in KIT, said method comprising: (a) obtaining a biological sample from the patient; (b) detecting the presence or absence of a KIT mutation selected from V654A in exon 13, N655T in exon 13, and T670I in exon 14 in the biological sample; and (c) administering a KIT inhibitor to the patient if the mutation is not detected.
1 . A method for treating a patient suffering from a malignant disease driven by activating mutations in KIT, said method comprising:
(a) obtaining a biological sample from the patient;
(b) detecting the presence or absence of a KIT mutation selected from V654A in exon 13, N655T in exon 13, and T670I in exon 14 in the biological sample; and
(c) administering a KIT inhibitor to the patient if the mutation is not detected.
2 . The method of claim 1 , wherein the KIT inhibitor is administered if one of V654A, N655T, and T670I is not detected.
3 . The method of claim 1 , wherein the KIT inhibitor is administered if two of V654A, N655T, and T670I are not detected.
4 . The method of claim 1 , wherein the KIT inhibitor is administered if none of V654A, N655T, and T670I are detected.
5 - 15 . (canceled)
16 . The method of claim 1 , wherein the malignant disease is cancer.
17 . The method of claim 16 , wherein the cancer is gastrointestinal stromal tumor (GIST).
18 . The method of claim 16 , wherein the cancer is selected from AML (acute myeloid leukemia), melanoma, seminoma, intercranial germ cell tumors, mediastinal B-cell lymphoma, Ewing's sarcoma, DLBCL (diffuse large B cell lymphoma), dysgerminoma, MDS (myelodysplastic syndrome), NKTCL (nasal NK/T-cell lymphoma), CMML (chronic myelomonocytic leukemia), brain cancers and systemic mastocytosis (smoldering (SSM), aggressive (ASM), SM with associated hemotologic non-mast cell lineage disease (SM-AHNMD), and mast cell leukemia (MCL).
19 - 23 . (canceled)
24 . The method of claim 1 , wherein the KIT inhibitor is avapritinib.
25 - 30 . (canceled)
31 . A method of predicting whether a patient suffering from a malignant disease will be responsive to treatment with a KIT inhibitor, comprising:
(a) obtaining a biological sample from a patient;
(b) detecting the presence or absence of a KIT mutation selected from V654A in exon 13, N655T in exon 13, and T670I in exon 14 in the biological sample; and
(c) if the KIT mutation is absent from the biological sample, concluding that the patient will be responsive to a KIT inhibitor, and if the KIT mutation is present, concluding the patient will be nonresponsive to treatment with a KIT inhibitor.
32 . The method of claim 31 , wherein if one of V654A, N655T, and T670I is not detected, concluding that the patient will be responsive to treatment with a KIT inhibitor.
33 . The method of claim 31 , wherein if two of V654A, N655T, and T670I are not detected, concluding that the patient will be responsive to treatment with a KIT inhibitor.
34 . The method of claim 31 , wherein if none of V654A, N655T, and T670I are detected, concluding that the patient will be responsive to treatment with a KIT inhibitor.
35 - 43 . (canceled)
44 . The method of claim 31 , wherein the malignant disease is cancer.
45 . The method of claim 44 , wherein the cancer is gastrointestinal stromal tumor (GIST).
46 . The method of claim 44 , wherein the cancer is selected from AML (acute myeloid leukemia), melanoma, seminoma, intercranial germ cell tumors, mediastinal B-cell lymphoma, Ewing's sarcoma, DLBCL (diffuse large B cell lymphoma), dysgerminoma, MDS (myelodysplastic syndrome), NKTCL (nasal NK/T-cell lymphoma), CMML (chronic myelomonocytic leukemia), brain cancers and systemic mastocytosis (smoldering (SSM), aggressive (ASM), SM with associated hemotologic non-mast cell lineage disease (SM-AHNMD), and mast cell leukemia (MCL).
47 - 53 . (canceled)
54 . A method of predicting whether a tumor will be responsive to treatment with a KIT inhibitor, comprising:
(a) obtaining a biological sample from a patient suffering from a cancer;
(b) detecting the presence or absence of a KIT mutation selected from V654A in exon 13, N655T in exon 13, and T670I in exon 14 in the biological sample; and
(c) if the KIT mutation is absent from the biological sample, concluding that the tumor will be responsive to treatment with a KIT inhibitor, and if the KIT mutation is present, concluding the tumor will be nonresponsive to treatment with a KIT inhibitor.
55 . The method of claim 54 , wherein if one of V654A, N655T, and T670I is not detected, concluding that the tumor will be responsive to treatment with a KIT inhibitor.
56 . The method of claim 54 , wherein if two of V654A, N655T, and T670I are not detected, concluding that the tumor will be responsive to treatment with a KIT inhibitor.
57 . The method of claim 54 , wherein if none of V654A, N655T, and T670I are detected, concluding that the tumor will be responsive to treatment with a KIT inhibitor.
58 - 65 . (canceled)
66 . The method of claim 65 , wherein the cancer is gastrointestinal stromal tumor (GIST).
67 - 97 . (canceled)